We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sigyn Therapeutics Inc (QB) | USOTC:SIGY | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.00 | 4.25 | 7.00 | 0.00 | 21:20:11 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Prior address and phone number:
2468 Historic Decatur Road, Suite 140 | ||
San Diego, CA | 92106 | |
(Address of principal executive offices) | (Zip Code) |
619.353.0800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
None | None | None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
On January 9, 2024, Sigyn Therapeutics, Inc. (the “Company”) entered into a Share Surrender Agreement with Craig Roberts, Chief Technical Officer and member of the board of directors of the Company (the “Shareholder”), whereas the parties agreed that 2,564,000 shares of common stock, par value $0.001, shall be surrendered by the Shareholder to the Company for cancellation and shall subsequently not be held as treasury shares or represent any claim against the Company whatsoever, effective immediately. The foregoing summary of the Share Surrender Agreement does not purport to be complete and is subject to, and qualified in its entirety by, such document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01 Other Events
As a result of the Share Surrender Agreement described in Item 1.01, and the conversion of various convertible notes since the date of the Company’s most recent Quarterly Report on Form 10-Q, the Company is reporting that as of the date hereof, it has 48,972,602 shares of common stock outstanding.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
10.1 | Share Surrender Agreement | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SIGYN THERAPEUTICS, INC. | ||
Date: January 11, 2024 | By: | /s/ James A. Joyce |
James A. Joyce, Chairman and CEO |
Exhibit 10.1
Cover |
Jan. 09, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 09, 2024 |
Entity File Number | 000-55575 |
Entity Registrant Name | SIGYN THERAPEUTICS, INC. |
Entity Central Index Key | 0001642159 |
Entity Tax Identification Number | 47-2573116 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 2468 Historic Decatur Road |
Entity Address, Address Line Two | Suite 140 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92106 |
City Area Code | 619 |
Local Phone Number | 368.2000 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
1 Year Sigyn Therapeutics (QB) Chart |
1 Month Sigyn Therapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions